|Systematic (IUPAC) name|
|(1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4- (diaminomethylideneamino)-2-hydroxy-cyclopentane- 1-carboxylic acid|
|Half-life||7.7 to 20.8 hour in patients with normal renal function|
|Mol. mass||328.40722 g/mol|
| (what is this?)
Peramivir is an experimental antiviral drug developed by BioCryst Pharmaceuticals for the treatment of influenza. It has been authorized for the emergency use of treatment of certain hospitalized patients with known or suspected 2009 H1N1 influenza.
Peramivir is already available in Japan as RAPIACTA (R) and also available in South Korea as PERAMIFLU. Peramivir is currently the only intravenous option for treating swine flu. The drug is in Phase III studies in US.
Use in treating Influenza A (H1N1) "Swine Flu"
In October 2009, it was reported that the experimental antiviral drug peramivir had been effective in treating serious cases of swine flu. On October 23, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization for Peramivir, allowing the use of the drug in intravenous form for hospitalized patients only in cases where the other available methods of treatment are ineffective or unavailable; for instance, if oseltamivir (Tamiflu) resistance develops and a person is unable to take Relenza via the inhaled route. The Emergency Use Authorization expired on June 23, 2010.
Biocryst also donated 1200 courses of treatment to the US department of Health and Human Services.
According to a research report published in June 2011, a novel variant of swine flu has emerged in Asia with a genetic adaptation giving some resistance to Roche's (ROG.VX) Tamiflu and GlaxoSmithKline's (GSK.L) Relenza, the two mainstay drugs used to tackle the disease. There was no significant reduction in sensitivity to Peramivir. 
Dosage and administration
Initial treatment courses are for 5 to 10 days duration. Treatment beyond 10 days is permitted depending on clinical presentation such as critical illness (e.g., respiratory failure or intensive care unit admission), continued viral shedding or unresolved clinical influenza illness.
- "Peramivir authorized for Emergency use". LifeHugger. 2009-12-04. Retrieved 2009-12-04.
- "HHS Pursues Advance Development of New Influenza Antiviral Drug" (Press release). US Department of Health and Human Services. 2007-01-04. Retrieved 2007-05-25.
- "Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza". National Institutes of Health. 2007-03-16. Retrieved 2007-05-25.
- "Evaluation of the Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-Threatening Influenza". National Institutes of Health. 2007-03-28. Retrieved 2007-05-25.
- "Life-Saving H1N1 Drug Unavailable to Most". CBS Evening News (Atlanta, GA, USA: CBS Interactive). 2009-10-19. Retrieved 2009-10-20.
- "Emergency Use Authorization Granted For BioCryst's Peramivir". Reuters. 2009-10-24.
- "FDA Authorizes Emergency Use of Intravenous Antiviral Peramivir for 2009 H1N1 Influenza for Certain Patients, Settings". Reuters. 2009-10-24.
- Hirschler, Ben (2011-06-10). "Swine flu starting to show resistance to drugs". Reuters.
- "Peramivir: Dosage and Administration". LifeHugger. 2009-12-04. Retrieved 2009-12-04.
- Peramivir: Requirements for Administration under EUA
- BioCryst Pharmaceuticals, Inc.
- Peramivir CDC/FDA EUA request form
- Peramivir Phase III Clinical Trials